Tuberculosis-related obstructive pulmonary disease (TOPD), as a high-burden disease in most countries, poses difficulties in the diagnosis and treatment of the disease when coexisting, and increases the risk of death for patients. Preliminary studies have shown that Yiqi Gubiao Wan has significant effects in relieving cough, alleviating asthma, expectorating phlegm, and delaying airway obstruction. The purpose of this study is to verify the therapeutic effect of Yiqi Gubiao pill on patients with TOPD through rigorous methodological design and to evaluate its safety. We will conduct a prospective, double-blind, randomized controlled trial. First, participants will be randomly assigned 1:1 to the Yiqi Gubiao pill treatment group and the Yiqi Gubiao pill placebo control group. This will be followed by a 12-week treatment. During the treatment period, we will measure and record the patients' lung function and quality of life. We will also score the patients' TCM symptoms. Finally, the safety of the medication will be assessed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Forced Vital Capacity
Timeframe: up to 4 weeks
the percentage of FVC predicted
Timeframe: up to 4 weeks
the ratio of FEV1 to FVC
Timeframe: up to 4 weeks
COPD Assessment Test (CAT) score
Timeframe: up to 4 weeks
modified Medical Research Council (mMRC) score
Timeframe: up to 4 weeks
Baseline Dyspnea Index (BDI) score
Timeframe: up to 4 weeks
Transition Dyspnea Index (TDI) score
Timeframe: up to 4 weeks